Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, randomized, controlled cohort study. This study will look at the effect of Ethinyl Estradiol 35mcg/Norethindrone 1mg and Ethinyl Estradiol 20 mcg/Norethindrone 1mg on postpartum depressive symptoms and sexual function scores when compared to a control group using no hormonal contraception. Depressive symptoms and sexual function will be measured using the Edinburgh Postnatal Depression Scale (EPDS), Arizona Sexual Experiences Scale (ASEX), and Brief Index of Sexual Functioning for Women (BISF-W). Participants will begin taking the medication at Week 3 postpartum, and these outcomes will be measured at baseline (0-1 day postpartum), Week 3, and Week 6-7. The investigators hypothesize that there will be an ethinyl estradiol dose related response in EPDS, ASEX, and BISF-W scores at Week 6-7, which would indicate a decrease in depressive symptoms and increase in sexual function in both of the oral contraceptive groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Safety and Efficacy of an Oral Contraceptive

NCT00391807

Contraception

COMPLETED PHASE3

A Study of Efficacy and Safety With the Transdermal Contraceptive System.

NCT00236769

Contraception Female Contraception

COMPLETED PHASE3

Study of Safety and Efficacy of an Oral Contraceptive

NCT00477633

Contraception

COMPLETED PHASE3

Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception

NCT02021097

Oral Contraceptive

UNKNOWN PHASE3

Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder

NCT00195559

Premenstrual Syndrome Menstruation Disturbances

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postpartum Depressive Mood Postpartum Sexual Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ethinyl Estradiol 35mcg/Noethindrone 1mg

21 day supply of Ethinyl Estradiol 35mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum

Group Type EXPERIMENTAL

Ethinyl Estradiol 35mcg/Norethindrone 1mg

Intervention Type DRUG

Ethinyl Estradiol 20mcg/Norethindrone 1mg

21 day supply of Ethinyl Estradiol 20mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum

Group Type EXPERIMENTAL

Ethinyl Estradiol 20mcg/Norethindrone 1mg

Intervention Type DRUG

No hormonal contraception

Women choosing copper IUD, spermicides, barrier methods, or sterilization (tubal ligation or partner vasectomy).

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ethinyl Estradiol 35mcg/Norethindrone 1mg

Intervention Type DRUG

Ethinyl Estradiol 20mcg/Norethindrone 1mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-45 year old women who desire contraception postpartum for at least 6 weeks.
* 18-45 year old women who choose not to use oral contraceptive medication postpartum for at least 6 weeks for the control group.

Exclusion Criteria

* Breastfeeding (although this may limit participant enrollment, combined oral contraceptives are contraindicated in this population).
* Delivery by cesarean section.
* Previous history of depression, mood disorders, or psychiatric disorders.
* Any condition (history or presence of) which contraindicates the use of combination OCs, including:
* Thrombophlebitis or thromboembolic disorders, known or suspected clotting disorders, deep vein thrombosis, thrombogenic valvulopathies or rhythm disorders.
* Pulmonary Embolism.
* Cerebrovascular or coronary artery disease or myocardial infarction.
* Diabetes mellitus.
* Migraine headaches with focal, neurological symptoms.
* Chronic renal disease.
* Uncontrolled or untreated hypertension.
* Cholestatic jaundice.
* Known or suspected carcinoma of the breast, endometrial carcinoma, or known or suspected estrogen-dependent neoplasia.
* Impaired liver function or disease, hepatic adenomas or carcinomas.
* Known hypersensitivity to estrogens and/or progestins.
* History of thyroid disorders.
* Recent alcohol or drug use.
* Smoking and age ≥35 or smokers who will become 35 years of age during the study.
* Known history of noncompliance with taking medication.

* Previous history of depression, mood disorders, or psychiatric disorders.
* Recent alcohol or drug use.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes